May 15, 2009

Xencor to Present Phase 1 Data on XmAb®2513 Antibody for Lymphomas at the American Society of Clinical Oncology Annual Meeting

First clinical data from a candidate developed using Xencor's antibody engineering platform

Monrovia, Calif. – May 15, 2009 – Xencor, Inc., an antibody discovery and development company, will present data from its Phase I study of XmAb®2513, an anti-CD30 Fc engineered humanized monoclonal antibody for the treatment of patients with relapsed Hodgkin lymphoma and anaplastic large cell lymphoma, on June 1 in a poster session at the American Society of Clinical Oncology Annual Meeting being held at the Orange County Convention Center in Orlando, Florida.

Poster Information

Date: Monday, June 1, 2009
Poster Session: 2:00 – 6:00 PM (Level 2, W240A)
Poster Discussion: 5:00 – 6:00 PM (Level 2, West Hall F1)
Abstract: #8531
Title: "Phase 1 study of an anti-CD30 Fc engineered humanized monoclonal antibody in Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL) patients: safety, pharmacokinetics (PK), immunogenicity and efficacy"

About XmAb2513

Xencor's lead candidate, XmAb®2513, entered clinical development in 2008 for the treatment of relapsed Hodgkin lymphoma and T cell lymphomas. XmAb®2513 is a humanized monoclonal antibody that targets the antigen CD30, a molecule expressed on the surface of a number of tumor cell types. XmAb®2513 has been engineered to contain an XmAb® Fc domain to greatly increase its cytotoxic potency. XmAb®2513 shows superior activity in recruiting primary human immune cells to kill tumor cells in in vitro models and is active in blocking tumor growth in rodent models. XmAb®2513 was humanized with Xencor's XmAb® Fv technology and was well-tolerated in primate models. XmAb®2513 is readily manufactured using standard monoclonal antibody production methods.

About Xencor

Xencor, Inc. engineers superior biotherapeutics using its proprietary Protein Design Automation® technology platform, and is a leader in the field of antibody Fc engineering to significantly improve antibody potency and half-life. The company is advancing multiple XmAb® antibody drug candidates into the clinic, led by anti-CD30 candidate XmAb®2513 in a Phase I clinical trial for the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma, and anti-CD19 candidate XmAb®5574 in pre-clinical development for the treatment for non-Hodgkin lymphoma and B-cell leukemia. With multiple partners, such as industry leaders Merck, Pfizer, CSL Ltd., Boehringer Ingelheim, MedImmune and Human Genome Sciences, Xencor is applying its suite of proprietary antibody Fc domains to improve antibody drug candidates for traits such as potency and sustained half-life. For more information, please visit www.xencor.com.

Contact
Kim Richards
Porter Novelli Life Sciences for Xencor
619-849-5377
krichards@pnlifesciences.com